1819 related articles for article (PubMed ID: 15721375)
1. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
2. Liposomal doxorubicin.
Tardi PG; Boman NL; Cullis PR
J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
6. Entrapment of small molecules and nucleic acid-based drugs in liposomes.
Fenske DB; Cullis PR
Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372
[TBL] [Abstract][Full Text] [Related]
7. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.
Tinkov S; Winter G; Coester C; Bekeredjian R
J Control Release; 2010 Apr; 143(1):143-50. PubMed ID: 20060861
[TBL] [Abstract][Full Text] [Related]
8. Use of liposomes as injectable-drug delivery systems.
Ostro MJ; Cullis PR
Am J Hosp Pharm; 1989 Aug; 46(8):1576-87. PubMed ID: 2672806
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
10. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting microencapsulation of drugs in liposomes.
Kulkarni SB; Betageri GV; Singh M
J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
[TBL] [Abstract][Full Text] [Related]
12. Liposomal anthracyclines.
Gabizon AA
Hematol Oncol Clin North Am; 1994 Apr; 8(2):431-50. PubMed ID: 8040147
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
14. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
17. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
18. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
Stevens PJ; Lee RJ
Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
[TBL] [Abstract][Full Text] [Related]
19. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
20. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]